,American Cancer Society. Cancer Facts and Figures, 2008. Atlanta, GA: American Cancer Society; 2008.Google Scholar

Reis, , Melbert, D, Krapcho, M., eds. SEER Cancer Statistics Review, 1975–2005. Bethesda, MD: National Cancer Institute; 2008.Google Scholar

Enzinger, PC, Mayer, RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–2252.CrossRefGoogle ScholarPubMed

Sial, SH, Catalano, MF. Gastrointestinal tract cancer in the elderly. Gastroenterol Clin. 2001;30(2):565–590.CrossRefGoogle ScholarPubMed

Khushalani, N.Cancer of the esophagus and stomach. Mayo Clin Proc. 2008;83(1):712–722.CrossRefGoogle ScholarPubMed

Shaheen, N, Ransohoff, DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. J Am Med Assoc. 2002;287(15): 1972–1981.CrossRefGoogle ScholarPubMed

Lagergren, J.Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?Gut. 2005;54(suppl 1):1–5.CrossRefGoogle ScholarPubMed

Iyer, RB, Silverman, PM, Tamm, EP. Diagnosis, staging, and follow-up of esophageal cancer. AJR Am J Roentgenol. 2003;181(3): 785–793.CrossRefGoogle ScholarPubMed

Pech, O, May, A, Günter, E. The impact of endoscopic ultrasound and computed tomography on the TNM staging of early cancer in Barrett's esophagus. Am J Gastroenterol. 2006;101(10):2223–2229.CrossRefGoogle ScholarPubMed

Bruzzi, JF, Munden, RF, Truong, MT. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007;27(6):1635–1652.CrossRefGoogle ScholarPubMed

Levine, EA, Farmer, MR, Clark, P. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243(4):472–478.CrossRefGoogle ScholarPubMed

Orringer, MB, Marshall, B, Chang, AC. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246(3): 363–372; discussion 372–374.CrossRefGoogle Scholar

Hulscher, JB, Sandick, JW, Boer, AG. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–1669.CrossRefGoogle ScholarPubMed

Audisio, RA, Veronesi, P, Ferrario, L. Elective surgery for gastrointestinal tumours in the elderly. Ann Oncol. 1997;8(4):317–326.CrossRefGoogle ScholarPubMed

Morita, M, Yoshida, R, Ohgaki, K. Clinical significance of an esophagectomy in patients 75 years of age or older based on an analysis of 1,000 operative cases with esophageal cancer. Paper presented at: 2008 Gastrointestinal Cancer Symposium; January 25–27, 2008; Orlando, FL.

Sykes, AJ, Burt, PA, Slevin, NJ. Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol. 1998;48(1):15–21.CrossRefGoogle Scholar

Cooper, JS, Guo, MD, Herskovic, A. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). J Am Med Assoc. 1999;281(17):1623–1627.CrossRefGoogle Scholar

Minsky, BD, Pajak, TF, Ginsberg, RJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–1174.CrossRefGoogle ScholarPubMed

Adelstein, DJ, Rice, TW, Rybicki, . Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000;18(10):2032–2039.CrossRefGoogle ScholarPubMed

Ilson, DH, Bains, M, Kelsen, DP. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 2003;21(15):2926–2932.CrossRefGoogle ScholarPubMed

Tougeron, D, DiFiore, F, Thureau, S. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer. 2008;99:1586–1592.CrossRefGoogle ScholarPubMed

Takeuchi, S, Ohtsu, A, Doi, T. A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol. 2007;30(6):607–611.CrossRefGoogle ScholarPubMed

Kelsen, DP, Winter, KA, Gunderson, LL. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24): 3719–3725.CrossRefGoogle ScholarPubMed

,Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002;359:1723–1733.Google Scholar

Cunningham, D, Allum, WH, Stenning, SP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefGoogle ScholarPubMed

Gebski, V, Burmeister, B, Smithers, BM. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–234.CrossRefGoogle ScholarPubMed

Bosset, JF, Gignoux, M, Triboulet, JP. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337(3):161–167.CrossRefGoogle ScholarPubMed

Burmeister, BH, Smithers, BM, Gebski, V. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–668.CrossRefGoogle ScholarPubMed

Walsh, TN, Noonan, N, Hollywood, D. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–467.CrossRefGoogle ScholarPubMed

Billingsley, KG, Maynard, C, Schwartz, DL. The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population: patient survival and outcome analysis. Cancer. 2001;92(5):1272–1280.3.0.CO;2-A>CrossRefGoogle ScholarPubMed

Smith, GL, Smith, BD, Buchholz, TA. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare cohort. Int J Radiat Oncol Biol Phys. 2009;74:482–489.CrossRefGoogle ScholarPubMed

Tew, WP, Kelsen, DP, Ilson, DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10(8):590–601.CrossRefGoogle ScholarPubMed

Sandler, AB, Kindler, HL, Einhorn, LH. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol. 2000;11(9):1161–1164.CrossRefGoogle ScholarPubMed

Ilson, DH, Saltz, L, Enzinger, P. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17(10):3270–3275.CrossRefGoogle ScholarPubMed

Muro, K, Hamaguchi, T, Ohtsu, A. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955–959.CrossRefGoogle ScholarPubMed

Kroep, JR, Pinedo, HM, Giaccone, G. Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol. 2004;15(2):230–235.CrossRefGoogle ScholarPubMed

Cunningham, D, Starling, N, Rao, S. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.CrossRefGoogle ScholarPubMed

Lorenzen, S, Hentrich, M, Haberl, C. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18(10):1673–1679.CrossRefGoogle ScholarPubMed

Jatoi, A, Foster, NR, Egner, J. Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials. Paper presented at: 44th American Society of Clinical Oncology Annual Meeting; May 30–June 3, 2008; Chicago, IL.

Trumper, M, Ross, PJ, Cunningham, D. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer. 2006;42(7):827–834.CrossRefGoogle ScholarPubMed

Clements, WD, Johnston, LR, McIlwrath, E. Self-expanding stents for malignant dysphagia. J R Soc Med. 1996;89(8):454–456.CrossRefGoogle ScholarPubMed

Cwikiel, W, Tranberg, KG, Cwikiel, M. Malignant dysphagia: palliation with esophageal stents – long-term results in 100 patients. Radiology. 1998;207(2):513–518.CrossRefGoogle ScholarPubMed

Laasch, HU, Marriott, A, Wilbraham, L. Effectiveness of open versus antireflux stents for palliation of distal esophageal carcinoma and prevention of symptomatic gastroesophageal reflux. Radiology. 2002;225(2):359–365.CrossRefGoogle ScholarPubMed

Spencer, GM, Thorpe, SM, Blackman, GM. Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: a randomised study. Gut. 2002;50(2):224–227.CrossRefGoogle ScholarPubMed

Gossner, L, May, A, Sroka, R. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid. Cancer. 1999;86(10):1921–1928.3.0.CO;2-N>CrossRefGoogle ScholarPubMed

Thomas, RJ, Abbott, M, Bhathal, PS. High-dose photoirradiation of esophageal cancer. Ann Surg. 1987;206(1):193–199.CrossRefGoogle ScholarPubMed

Dicken, BJ, Bigam, DL, Cass, C. Gastric adenocarcinoma. Ann Surg. 2005;241(1):27–39.Google ScholarPubMed

Lochhead, P, El-Omar, EM. Gastric cancer. Br Med Bull. 2008;85:87–100.CrossRefGoogle ScholarPubMed

Allum, WH, Griffin, SM, Colin-Jones, D. Guidelines for the management of oesophageal and gastric cancer. Gut. 2002;50(suppl 5):1–23.CrossRefGoogle ScholarPubMed

Gunderson, LL, Donohue, JH, Alberts, SR. Cancer of the stomach. In: Abeloff, MD, Armitage, JO, Niederhuber, JE., eds. Clinical Oncology. Philadelphia: Elsevier; 2004:1819–1875.Google Scholar

Fuchs, CS, Mayer, RJ. Gastric carcinoma. N Engl J Med. 1995;333(1):32–41.CrossRefGoogle ScholarPubMed

Huntsman, DG, Carneiro, F, Lewis, FR. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344(25):1904–1909.CrossRefGoogle ScholarPubMed

El-Serag, HB, Mason, AC, Petersen, N. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002;50:368–372.CrossRefGoogle ScholarPubMed

Naylor, GM, Gotoda, T, Dixon, M. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006;55:1545–1552.CrossRefGoogle ScholarPubMed

Wong, BC, Lam, SK, Wong, WM. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. J Am Med Assoc. 2004;291(2):187–194.CrossRefGoogle Scholar

Uemura, N, Okamoto, S, Yamamoto, S. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11): 784–789.CrossRefGoogle ScholarPubMed

You, W, Zhang, L, Gail, MH. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst. 2000;92(19):1607–1612.CrossRefGoogle ScholarPubMed

Huang, X, Tajima, K, Hamajima, N. Effects of dietary, drinking, and smoking habits on the prognosis of gastric cancer. Nutr Cancer. 2000;38(1):30–36.CrossRefGoogle ScholarPubMed

Devesa, SS, Blot, WJ, Fraumeni, FJ. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049–2053.3.0.CO;2-2>CrossRefGoogle ScholarPubMed

Souza, RF, Spechler, SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin. 2005;55:334–351.CrossRefGoogle ScholarPubMed

Ramon, JM, Serra, L, Cerdo, C. Dietary factors and gastric cancer risk. Cancer. 1993;71(5):1731–1735.3.0.CO;2-X>CrossRefGoogle ScholarPubMed

Vecchia, CL, Negri, E, Franceschi, S. Family history and risk of stomach and colorectal cancer. Cancer. 1992;70(1):50–55.3.0.CO;2-I>CrossRefGoogle ScholarPubMed

Bozzetti, F, Marubini, E, Bonfanti, G. Subtotal versus total gastrectomy for gastric cancer. Ann Surg. 1999;230(2):170–178.CrossRefGoogle ScholarPubMed

velde, CJ.Gastric cancer: staging and surgery. Ann Oncol. 2002;13:3–6.CrossRefGoogle ScholarPubMed

Bonenkamp, JJ, Hermans, J, Sasako, M. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–914.CrossRefGoogle ScholarPubMed

Hartgrink, HH, Velde, CJ, Putter, H. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–2077.CrossRefGoogle ScholarPubMed

Cuschieri, A, Weeden, S, Fielding, J. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79(9/10): 1522–1530.CrossRefGoogle ScholarPubMed

Degiuli, M, Sasako, M, Calgaro, M. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of Italian gastric cancer study group (IGCSG) randomized surgical trial. Eur J Surg Oncol. 2004;30(3):303–308.CrossRefGoogle Scholar

Wu, CW, Hsiung, CA, Lo, SS. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Brit J Surg. 2004;91:283–287.CrossRefGoogle ScholarPubMed

Wu, C, Hsiung, CA, Lo, S. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet. 2006;7:309–315.CrossRefGoogle ScholarPubMed

Sasako, M, Sano, T, Yamamoto, S. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–462.CrossRefGoogle ScholarPubMed

McCulloch, P, Ward, J, Tekkis, PP. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. Br Med J. 2003;327(22):1–6.CrossRefGoogle ScholarPubMed

Yasuda, K, Sonoda, H, Shiroshita, H. Laparoscopically assisted distal gastrectomy for early gastric cancer in the elderly. Brit J Surg. 2004;91:1061–1065.CrossRefGoogle ScholarPubMed

Hartgrink, HH, Putter, H, Kranenbarg, EK. Value of palliative resection in gastric cancer. Brit J Surg. 2002;89:1438–1443.CrossRefGoogle ScholarPubMed

Shimada, K, Ajani, J. Adjuvant therapy for gastric carcinoma patients in the past 15 years. Cancer. 1999;86(9):1657–1668.3.0.CO;2-J>CrossRefGoogle ScholarPubMed

Vita, F, Giuliani, F, Galizia, G. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol. 2007;18(suppl 6): 120–123.Google ScholarPubMed

Hermans, J, Bonenkamp, JJ, Boon, MC. Adjuvant therapy after curative resection for gastric caner: meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441–1447.CrossRefGoogle Scholar

Earle, CC, Maroun, JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer. 1999;35(7): 1059–1064.CrossRefGoogle Scholar

Mari, E, Floriani, I, Tinazzi, A. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. Ann Oncol. 2000;11:837–843.CrossRefGoogle Scholar

Januger, K, Halstrom, L, Glimelius, B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168: 597–608.CrossRefGoogle Scholar

Liu, TS, Wang, Y, Chen, SY. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol. 2008;34:1208–1216.CrossRefGoogle ScholarPubMed

Costanzo, FD, Gasperoni, S, Manzione, L. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100(6):388–398.CrossRefGoogle ScholarPubMed

Cascinu, S, Labianca, R, Barone, C. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leukovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst. 2007;99(8): 601–607.CrossRefGoogle Scholar

Vita, F, Giuliani, F, Orditura, M. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 study). Ann Oncol. 2007;18: 1354–1358.CrossRefGoogle Scholar

Sakuramoto, S, Sasako, M, Yamaguchi, T. Adjuvant chemotherapy for gastric cancer with S-1, and oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820.CrossRefGoogle ScholarPubMed

Macdonald, JS, Smalley, SR, Benedetti, J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730.CrossRefGoogle ScholarPubMed

Ajani, JA, Mansfield, PF, Janjan, N. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22(14):2774–2780.CrossRefGoogle ScholarPubMed

Wagner, AD, Grothe, W, Haerting, J. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate date. J Clin Oncol. 2006;24(18): 2903–2909.CrossRefGoogle Scholar

Cutsem, E, Moiseyenko, VM, Tjulandin, S. Phase III study of docetaxel plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24(31):4991–4997.CrossRefGoogle ScholarPubMed

Koizumi, W, Narahara, H, Hara, T. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–221.CrossRefGoogle ScholarPubMed

Al-Batran, S, Hartmann, JT, Probst, S. Phase III trial in metastatic gastroesophogeal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–1442.CrossRefGoogle ScholarPubMed

Santini, D, Graziano, F, Catalano, V. Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patient with advanced gastric cancer. Paper presented at: 40th American Society of Clinical Oncology Annual Meeting; June 5–8, 2004; New Orleans, LA.

Azzarello, D, Giuffre, C, Panuccio, V. First line chemotherapy with FOLFOX 4 in elderly patients (>65 years) with advanced or metastatic gastric cancer: a pilot study. Paper presented at: 42nd American Society of Clinical Oncology Annual Meeting; June 2–6, 2006; Atlanta, GA.

Choi, I, Lee, K, Oh, D. Oxaliplatin, 5-fluorouracil and folinic acid as first-line chemotherapy for elderly patients with advanced gastric cancer. Paper presented at: 42nd American Society of Clinical Oncology Annual Meeting; June 2–6, 2006; Atlanta, GA.

Seol, YM, Song, MK, Choi, YJ. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study. Jpn J Clin Oncol. 2009;39(1):43–48.CrossRefGoogle ScholarPubMed

Yates, MR, Morgan, , Baron, TH. Palliation of malignant gastric and small intestinal strictures with self-expandable metal stents. Endoscopy. 1998;30(3):266–272.CrossRefGoogle ScholarPubMed

Telford, JJ, Carr-Locke, DL, Baron, TH. Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study. Gastrointestinal Endosc. 2004;60(6):916–920.CrossRefGoogle ScholarPubMed

Norberto, L, Ranzato, R, Marino, S. Endoscopic palliation of esophageal and cardial cancer: neodymium-yttrium aluminum garnet laser therapy. Dis Esophagus. 1999;12(4): 294–296.CrossRefGoogle ScholarPubMed

Sayag-Beaujard, AC, Francois, Y, Glehen, O. Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Anticancer Res. 1999;19(2B):1375–1382.Google ScholarPubMed

Leichman, L, Silberman, H, Leichman, CG. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol. 1992;10(12): 1933–1942.CrossRefGoogle ScholarPubMed